Lung microbiome dynamics in COPD exacerbations

European Respiratory Journal

Volumn 47, Issue 4, 2016, Pages 1082-1092

  Wang, Zhang ^a   Bafadhel, Mona ^b   Haldar, Koirobi ^c,e   Spivak, Aaron ^a   Mayhew, David ^a   Miller, Bruce E ^a   Tal Singer, Ruth ^a   Johnston, Sebastian L ^d   Ramsheh, Mohammadali Yavari ^c   Barer, Michael R ^c   Brightling, Christopher E ^c,e   Brown, James R ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; INTERLEUKIN 8; MATRILYSIN; RNA 16S; BIOLOGICAL MARKER; CHEMOKINE; IL8 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BACTEROIDETES; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY STRUCTURE; DISEASE EXACERBATION; EOSINOPHILIA; FEMALE; FIRMICUTES; HAEMOPHILUS; HUMAN; LUNG MICROBIOME; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; MICROBIOME; MORAXELLA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEOBACTERIA; SPUTUM; STREPTOCOCCUS; DNA SEQUENCE; GENETICS; LONGITUDINAL STUDY; LUNG; METABOLISM; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; QUALITY CONTROL; VERY ELDERLY;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHEMOKINES; FEMALE; HUMANS; INTERLEUKIN-8; LONGITUDINAL STUDIES; LUNG; MALE; MICROBIOTA; MIDDLE AGED; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY CONTROL; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA; SPUTUM;

EID: 84964045832     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01406-2015     Document Type: Article

References (38)

1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397-412.
2. Franklin W, Lowell FC, Michelson AL, et al. Chronic obstructive pulmonary emphysema; a disease of smokers. Ann Intern Med 1956; 45: 268-274.
3. Taraseviciene-Stewart L, Douglas IS, Nana-Sinkam PS, et al. Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease? Proc Am Thorac Soc 2006; 3: 687-690.
4. Miravitlles M, Espinosa C, Fernández-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40-46.
5. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108: Suppl. 2, 43S-52S.
6. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-1505.
7. Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-1320.
8. Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol 2014; 52: 2813-2823.
9. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome following rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1224-1231.
10. Zakharkina T, Heinzel E, Koczulla RA, et al. Analysis of the airway microbiota of healthy individuals and patients with chronic obstructive pulmonary disease by T-RFLP and clone sequencing. PLoS One 2013; 8: e68302.
11. Rogers GB, Carroll MP, Serisier DJ, et al. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004; 42: 5176-5183.
12. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-671.
13. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
14. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
15. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: Suppl. 2, 398S-401S.
16. National Institute for Health and Clinical Excellence. Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management. London, National Institute for Health and Clinical Excellence, 2010.
17. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7: 335-336.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach for multiple testing. J R Statist Soc B 1995; 57: 289-300.
19. Erkan L, Uzun O, Findik S, et al. Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3: 463-467.
20. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: A state-of-The-art review. Clin Microbiol Rev 2001; 14: 336-363.
21. Parameswaran GI, Wrona CT, Murphy TF, et al. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis 2009; 9: 178.
22. Faust K, Sathirapongsasuti JF, Izard J, et al. Microbial co-occurrence relationships in the human microbiome. PLoS Comput Biol 2012; 8: e1002606.
23. Millares L, Ferrari R, Gallego M, et al. Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2014; 33: 1101-1111.
24. Bathoorn E, Kerstjens H, Postma D, et al. Airways inflammation and treatment during acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 217-229.
25. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The REDUCE randomized clinical trial. JAMA 2013; 309: 2223-2231.
26. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997; 111: 732-743.
27. Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014; 384: 691-702.
28. Fisher CK, Mehta P. Identifying keystone species in the human gut microbiome from metagenomic timeseries using sparse linear regression. PLoS One 2014; 9: e102451.
29. Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol 2012; 10: 717-725.
30. Larsson K. Inflammatory markers in COPD. Clin Respir J 2008; 2: Suppl 1, 84-87.
31. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001; 34: Suppl. 50s-59s.
32. Bautista MV, Chen Y, Ivanova VS, et al. IL-8 regulates mucin gene expression at the posttranscriptional level in lung epithelial cells. J Immunol 2009; 183: 2159-2166.
33. Zhang X, Zheng H, Zhang H, et al. Increased interleukin (IL)-8 and decreased IL-17 production in chronic obstructive pulmonary disease (COPD) provoked by cigarette smoke. Cytokine 2011; 56: 717-725.
34. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-120.
35. Ishii KJ, Koyama S, Nakagawa A, et al. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 2008; 3: 352-363.
36. Kistler A, Avila PC, Rouskin S, et al. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity. J Infect Dis 2007; 196: 817-825.
37. Cui L, Lucht L, Tipton L, et al. Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease. Am J Respir Crit Care Med 2015; 191: 932-942.
38. Ghannoum MA, Jurevic RJ, Mukherjee PK, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog 2010; 6: e1000713.